Cox-2 expression in ovarian malignancies. A review of the clinical aspects

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 146, Issue 2, 2009, Pages 129-132

  Menczer, Joseph ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

COX 2 expression; Outcome; Ovarian malignancies; Prognostic factors

Indexed keywords

CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DOCETAXEL; GROWTH FACTOR; MITOGENIC AGENT; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PACLITAXEL; VASCULOTROPIN;

CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CLINICAL FEATURE; CLINICAL PRACTICE; CYTOTOXICITY; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

EID: 70349510443     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.05.030     Document Type: Review

References (44)

1. Koki A.T., and Masferrer J.L. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9 2 Suppl (2002) 28-35
2. Pereg D., and Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Int Med 258 (2005) 115-123
3. Denkert C., Winzer K.J., and Hauptman S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 4 (2004) 428-433
4. Ogino S., Kirkner G.J., Nosho K., et al. Cyclooxogenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14 (2008) 8221-8227
5. Liao Z., Mason K.A., and Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?. Drugs 67 (2007) 821-845
6. Gasparini G., Longo R., Sarmiento R., and Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 4 (2003) 605-615
7. Ohno S., Ohno Y., Suzuki N., Inagawa H., Kohchi C., Soma G., et al. Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25 (2005) 3679-3687
8. Young J.L., Jazaeri A.A., Darus C.J., and Modesitt S.C. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109 (2008) 140-145
9. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
10. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., and Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61 (2001) 7305-7309
11. Matsumoto Y., Ishiko O., Deguchi M., Nakagawa E., and Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 8 (2001) 31-36
12. Landen Jr. C.N., Mathur S.P., Richardson M.S., and Creasman W.T. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188 (2003) 1174-1176
13. Shigemasa K., Tian X., Gu L., Shiroyama Y., Nagai N., and Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22 (2003) 99-105
14. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., et al. Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160 (2002) 893-903
15. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A., et al. Expression of inducible nitric oxide synthase and cycloxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 92 (2004) 806-812
16. Raspollini M.R., Amunni G., Villanucci A., Boddi V., and Taddei G.L. Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15 255 (2005) 60
17. Raspollini M.R., Amunni G., Villanucci A., Boddi V., and Taddei G.L. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Acta Obstet Gynecol Scand 85 (2006) 493-498
18. Ferrandina G., Ranelletti F.O., Lauriola L., Fanfani F., Legge F., Mottolese M., et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and her-2/neu expression in ovarian cancer. Gynecol Oncol 85 (2002) 305-310
19. Ferrandina G., Lauriola L., Zannoni G.F., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13 (2002) 1205-1211
20. Ferrandina G., Ranelletti F.O., Martinelli E., Paglia A., Zannoni G.F., and Scambia G. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 6 (2006) 182
21. Erkinheimo T.L., Lassus H., Finne P., et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER 2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10 (2004) 538-545
22. Erkinheimo T.L., Sivula A., Lassus H., Heinonen M., Furneaux H., Haglund C., et al. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol 99 (2005) 14-19
23. Khalifeh I., Munkarah A.R., Lonardo F., Malone J., Morris R., Lawrence W.D., et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 23 (2004) 162-169
24. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92 (2004) 927-935
25. Ozel E., Pestereli H.E., Simsek T., Erdogan G., and Karaveli F.S. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?. Int J Gynecol Cancer 16 (2006) 549-555
26. Singhal P.K., Spiegel G., Driscoll D., Odunsi K., and Lele S. Rodabaugh KJ. Cyclooxygenase 2 expression in serous tumors of the ovary. Int J Gynecol Pathol 24 (2005) 62-66
27. Lee J.S., Choi Y.D., Lee J.H., Nam J.H., Choi C., Lee M.C., et al. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer 16 Suppl 1 (2006) 247-253
28. Li M., Qi S.Y., Wang Y., Feng S.X., Zhang B.Z., and Wang R. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch Gynecol Obstet 2721 (2005) 48-52
29. Ferrandina G., Zannoni G.F., Ranelletti F.O., Legge F., Gessi M., Salutari V., et al. Cyclooxygenase-2 expression in borderline ovarian tumors. Gynecol Oncol 95 (2004) 46-51
30. Roland I.H., Yang W.L., Yang D.H., Daly M.B., Ozols R.F., Hamilton T.C., et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphological changes in prophylactic oophorectomies. Cancer 98 (2003) 2607-2623
31. Fujimoto J., Toyoki H., Sakaguchi H., Jahan I., Alam S.M., and Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep 15 (2006) 21-25
32. Ali-Fehmi R., Che M., Khalifeh I., Malone J.M., Morris R., Lawrence W.D., et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98 (2003) 1423-1429
33. Ali-Fehmi R., Morris R.T., Bandyopadhya S., Che M., Schimp V., Malone J.M., et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192 (2005) 819-825
34. Subbaramaiah K., Hart J.C., Norton L., and Dannenberg A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. J Biol Chem 275 (2000) 14838-14845
35. Surowiak P., Materna V., Denkert C., Kaplenko I., Spaczynski M., Dietel M., et al. Significance of cyclooxygenase 2 and MDR1/P glycoporotein coexpression in ovarian cancers. Cancer Lett 235 (2006) 272-280
36. Materna V., Pleger J., Hoffmann U., and Lage H. RNA expression of MDR1/P glyocprotein, DNA-topoisomerase, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94 (2004) 152-160
37. Vital-Reyes V., Rodriguez-Burford C., Chhieng D.C., and Oelschlager D.K. Reyes Fuentes A, Barnes M, Grizzle WE. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med ResV 37 (2006) 689-695
38. Barnes A.P., Miller B.E., and Kucera G.L. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol 104 (2007) 443-450
39. Munkarah A.R., Genhai Z., Morris R., Baker V.V., Deppe G., and Diamond M.P. Saed GM Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 88 (2003) 429-433
40. Munkarah A.R., Ali-Fehmi R., Jiang J.Z., Elhammady E., Malone Jr. J.M., and Saed G.M. The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer. Anticancer Drugs 18 (2007) 889-896
41. Barnes M.N., Chhieng D.F., Dreher M., Jones J.L., Grizzle W.E., Jones L., et al. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol 98 (2005) 376-382
42. Sørensen H.T., Skriver M.V., Friis S., McLaughlin J.K., Blot W.J., and Baron J.A. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer 14 92 (2005) 594-596
43. Lacey Jr. J.V., Sherman M.E., Hartge P., Schatzkin A., and Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 1082 (2004) 281-286
44. Sumi T., Ishiko O., Yoshida H., Hyun Y., Nakagawa E., Hirai K., et al. Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med 8 (2001) 495-498